GSK plc
GLAXF
Other OTC25.50
USD
-1.13
- -
CIK
0001131399
ISIN
GB00BN7SWP63
Return %
Stock
S&P500
1Y
27.37
25.25
3Y
48.51
70.54
5Y
-2.63
77.82
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Luke Victor Miels
- Full Time Employees
- 68,629
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Address
- 980 Great West Road Brentford United Kingdom TW8 9GS
- IPO Date
- Jan 5, 2010
- CIK
- 0001131399
- Website
- gsk.com
- Similar Companies
- Business
- GSK plc is a global biopharmaceutical company specializing in the research, development, manufacture, and marketing of vaccines, specialty medicines, and consumer healthcare products. Its main product offerings include prescription pharmaceuticals in respiratory, immunology, inflammation, oncology, and HIV therapeutic areas; a broad portfolio of vaccines; and recently divested consumer healthcare products following separation from its prior consumer joint venture. GSK operates across more than 80 countries and markets its products in 122 countries, with headquarters in Brentford, United Kingdom. Founded in 1715 and rebranded as GSK plc in 2022, the company focuses primarily on biopharmaceuticals following its strategic demerger of the consumer healthcare segment. In recent major developments, GSK has accelerated its growth in specialty medicines through several strategic acquisitions and product launches. Noteworthy transactions include the acquisition of IDRx, a US-based biotechnology firm specializing in gastrointestinal stromal tumor treatments, finalized in early 2025 for approximately $1.15 billion, reinforcing its oncology portfolio. In 2024, GSK completed acquisition of Aiolos Bio, focusing on respiratory and inflammatory diseases, and Elsie Biotechnologies to enhance its oligonucleotide drug capabilities. The company announced five major new product approvals slated for 2025, including Blenrep for multiple myeloma and depemokimab for severe asthma, signaling strong pipeline progress with over 70 specialty medicines and vaccines in clinical development. Strategic alliances have also been formed, such as a research collaboration with Flagship Pioneering to advance therapies in respiratory, immunology, and inflammation. GSK’s business segments concentrate on specialty medicines including respiratory, immunology, oncology, and HIV, alongside vaccines, with sales growth driven notably by its specialty medicines portfolio. The company operates mainly in the U.S., Europe, and the UK markets. GSK has refined its corporate structure since its 2022 reorganization, prioritizing investment in innovation and R&D to maintain leadership in advanced biopharmaceutical treatments. Its long-term outlook expects sales exceeding £40 billion by 2031, supported by sustained research and development investments and a strong late-stage clinical pipeline. The company employs over 68,000 people globally and maintains a primary listing on the London Stock Exchange as part of the FTSE 100 Index. In leadership changes, GSK appointed Luke Miels as CEO starting in 2026, succeeding Emma Walmsley who led the company through a period of transformation and growth. Overall, GSK continues to evolve as a focused biopharma leader with an expanding portfolio in specialty medicines and vaccines, driven by strategic acquisitions, strong pipeline developments, and global market presence.
UBS says UK stocks are better supported but not broadly so, as earnings lead while sentiment drags
GSK plc (GSK) Q1 2026 Earnings Call Transcript